Cargando…
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants
The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients p...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737523/ https://www.ncbi.nlm.nih.gov/pubmed/36652889 http://dx.doi.org/10.1016/j.ejca.2022.11.030 |
| _version_ | 1784847310739472384 |
|---|---|
| author | Giesen, Nicola Busch, Elena Schalk, Enrico Beutel, Gernot Rüthrich, Maria M. Hentrich, Marcus Hertenstein, Bernd Hirsch, Hans H. Karthaus, Meinolf Khodamoradi, Yascha Koehler, Philipp Krüger, William Koldehoff, Michael Krause, Robert Mellinghoff, Sibylle C. Penack, Olaf Sandherr, Michael Seggewiss-Bernhardt, Ruth Spiekermann, Karsten Sprute, Rosanne Stemler, Jannik Weissinger, Florian Wörmann, Bernhard Wolf, Hans-Heinrich Cornely, Oliver A. Rieger, Christina T. von Lilienfeld-Toal, Marie |
| author_facet | Giesen, Nicola Busch, Elena Schalk, Enrico Beutel, Gernot Rüthrich, Maria M. Hentrich, Marcus Hertenstein, Bernd Hirsch, Hans H. Karthaus, Meinolf Khodamoradi, Yascha Koehler, Philipp Krüger, William Koldehoff, Michael Krause, Robert Mellinghoff, Sibylle C. Penack, Olaf Sandherr, Michael Seggewiss-Bernhardt, Ruth Spiekermann, Karsten Sprute, Rosanne Stemler, Jannik Weissinger, Florian Wörmann, Bernhard Wolf, Hans-Heinrich Cornely, Oliver A. Rieger, Christina T. von Lilienfeld-Toal, Marie |
| author_sort | Giesen, Nicola |
| collection | PubMed |
| description | The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adaptations of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data. |
| format | Online Article Text |
| id | pubmed-9737523 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The Authors. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97375232022-12-12 AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants Giesen, Nicola Busch, Elena Schalk, Enrico Beutel, Gernot Rüthrich, Maria M. Hentrich, Marcus Hertenstein, Bernd Hirsch, Hans H. Karthaus, Meinolf Khodamoradi, Yascha Koehler, Philipp Krüger, William Koldehoff, Michael Krause, Robert Mellinghoff, Sibylle C. Penack, Olaf Sandherr, Michael Seggewiss-Bernhardt, Ruth Spiekermann, Karsten Sprute, Rosanne Stemler, Jannik Weissinger, Florian Wörmann, Bernhard Wolf, Hans-Heinrich Cornely, Oliver A. Rieger, Christina T. von Lilienfeld-Toal, Marie Eur J Cancer Original Research The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adaptations of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data. The Authors. Published by Elsevier Ltd. 2023-03 2022-12-10 /pmc/articles/PMC9737523/ /pubmed/36652889 http://dx.doi.org/10.1016/j.ejca.2022.11.030 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Original Research Giesen, Nicola Busch, Elena Schalk, Enrico Beutel, Gernot Rüthrich, Maria M. Hentrich, Marcus Hertenstein, Bernd Hirsch, Hans H. Karthaus, Meinolf Khodamoradi, Yascha Koehler, Philipp Krüger, William Koldehoff, Michael Krause, Robert Mellinghoff, Sibylle C. Penack, Olaf Sandherr, Michael Seggewiss-Bernhardt, Ruth Spiekermann, Karsten Sprute, Rosanne Stemler, Jannik Weissinger, Florian Wörmann, Bernhard Wolf, Hans-Heinrich Cornely, Oliver A. Rieger, Christina T. von Lilienfeld-Toal, Marie AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| title | AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| title_full | AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| title_fullStr | AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| title_full_unstemmed | AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| title_short | AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| title_sort | agiho guideline on evidence-based management of covid-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |
| topic | Original Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737523/ https://www.ncbi.nlm.nih.gov/pubmed/36652889 http://dx.doi.org/10.1016/j.ejca.2022.11.030 |
| work_keys_str_mv | AT giesennicola agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT buschelena agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT schalkenrico agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT beutelgernot agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT ruthrichmariam agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT hentrichmarcus agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT hertensteinbernd agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT hirschhansh agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT karthausmeinolf agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT khodamoradiyascha agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT koehlerphilipp agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT krugerwilliam agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT koldehoffmichael agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT krauserobert agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT mellinghoffsibyllec agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT penackolaf agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT sandherrmichael agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT seggewissbernhardtruth agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT spiekermannkarsten agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT spruterosanne agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT stemlerjannik agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT weissingerflorian agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT wormannbernhard agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT wolfhansheinrich agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT cornelyolivera agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT riegerchristinat agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants AT vonlilienfeldtoalmarie agihoguidelineonevidencebasedmanagementofcovid19incancerpatients2022updateonvaccinationpharmacologicalprophylaxisandtherapyinlightoftheomicronvariants |